Search results for "chronic infection"

showing 10 items of 35 documents

Efficient and reproducible experimental infections of rats with Blastocystis spp.

2018

Although Blastocystis spp. infect probably more than 1 billion people worldwide, their clinical significance is still controversial and their pathophysiology remains poorly understood. In this study, we describe a protocol for an efficient and reproducible model of chronic infection in rats, laying the groundwork for future work to evaluate the pathogenic potential of this parasite. In our experimental conditions, we were unable to infect rats using vacuolar forms of an axenically cultivated ST4 isolate, but we successfully established chronic infections of 4 week-old rats after oral administration of both ST3 and ST4 purified cysts isolated from human stool samples. The infection protocol …

0301 basic medicinemodèle animal[SDV]Life Sciences [q-bio]lcsh:MedicineBlastocystis Infections[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]souris[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityFecesblastocyste[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Medicine and Health SciencesParasite hostingCystratmodèle pour les maladies humaineslcsh:Scienceblastocyst stageProtozoansGastrointestinal tractMice Inbred BALB CMice Inbred C3HMultidisciplinarybiologyaxenic cultureEukaryotaPathophysiologyanimal models3. Good health[SDV] Life Sciences [q-bio]Separation ProcessesExperimental Organism SystemsAnatomyResearch ArticlemiceColonMouse ModelsResearch and Analysis MethodsMicrobiologyculture axeniqueMicrobiology03 medical and health sciencesModel OrganismsmedicineParasitic DiseasesAnimalsHumansClinical significanceAnimal Models of Disease[SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunityDistillationBlastocystisHost (biology)lcsh:ROrganismsBiology and Life Sciencesbiology.organism_classificationmedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyParasitic ProtozoansRatsMice Inbred C57BLGastrointestinal TractChronic infectionDisease Models AnimalAnimal Models of Infection030104 developmental biologyBlastocystisAnimal Studieslcsh:Q[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyParasitic Intestinal DiseasesDigestive System
researchProduct

Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner

2007

Gammaherpesviruses are important pathogens whose lifelong survival in the host depends critically on their capacity to establish and reactivate from latency, processes regulated by both viral genes and the host immune response. Previous work has demonstrated that gamma interferon (IFN-gamma) is a key regulator of chronic infection with murine gammaherpesvirus 68 (gammaHV68), a virus that establishes latent infection in B lymphocytes, macrophages, and dendritic cells. In mice deficient in IFN-gamma or the IFN-gamma receptor, gammaHV68 gene expression is altered during chronic infection, and peritoneal cells explanted from these mice reactivate more efficiently ex vivo than cells derived from…

1109 Insect Sciencemedicine.medical_treatmentImmunologyCellSpleen610 Medicine & healthBiology10263 Institute of Experimental ImmunologyMicrobiologyInterferon-gammaGammaherpesvirinaeImmune systemVirologyVirus latencymedicineAnimalsHumansInterferon gammaDiphtheria toxinB-Lymphocytes2403 ImmunologyMacrophages2404 MicrobiologyHerpesviridae Infectionsmedicine.diseaseVirus LatencyCell biologyChronic infectionCytokinemedicine.anatomical_structureInsect ScienceImmunology2406 VirologyPathogenesis and Immunity570 Life sciences; biologyVirus Activationmedicine.drug
researchProduct

HLA-DRB1*1301 AND *1302 protect against chronic hepatitis B

1997

Abstract Background/Aims: The outcome of acute hepatitis B infection may be influenced by host factors like the major histocompatibility complex (MHC). We have investigated MHC class I and class II antigens in patients with chronic hepatitis B compared to a healthy control population. To confirm the findings of this first study we performed a second study in a group of subjects who had spontaneously recovered from acute hepatitis B infection. Methods: Frequencies of MHC class I and class II antigens were analyzed in patients with chronic hepatitis B virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotypes were d…

AdultHepatitis B virusRemission SpontaneousPopulationEnzyme-Linked Immunosorbent AssayMajor histocompatibility complexmedicine.disease_causePolymerase Chain ReactionHLA-DQ alpha-ChainsVirusHLA-DQ AntigensMHC class ImedicineHumansSerologic TestsProspective StudiesHepatitis B AntibodieseducationHLA-DRB1AllelesHepatitis B viruseducation.field_of_studyMHC class IIHepatitis B Surface AntigensHepatologybiologyHLA-DR AntigensHepatitis BVirologyChronic infectionImmunoglobulin GChronic DiseaseDNA ViralImmunologybiology.proteinHLA-DRB1 ChainsJournal of Hepatology
researchProduct

Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients

2007

Chronic infection by Hepatitis C Virus (HCV) causes liver fibrosis, which is accelerated by unknown mechanisms in patients with HIV-1 coinfection. The evolution of HCV quasispecies in this setting of coinfection is not fully understood. To compare HCV quasispecies between HIV-HCV coinfection and HCV monoinfection, we sequenced 340 HCV clones from the HVR-1 and NS3 regions at two different time points in two groups of treatment-naive patients with HCV-1a infection: (1) HIV-HCV positive (n=6); and (2) HIV negative-HCV positive (n=3). In HCV/HIV coinfection, we found a trend for reduced HCV genetic complexity and diversity, and a trend towards reduced dN/dS ratios in the HVR-1 region, especial…

AdultMaleCancer ResearchHepatitis C virusHepacivirusMolecular Sequence DataSequence HomologyHIV InfectionsHepacivirusViral quasispeciesViral Nonstructural Proteinsmedicine.disease_causeArticleViral ProteinsAcquired immunodeficiency syndrome (AIDS)VirologymedicineCluster AnalysisHumansPhylogenyNS3biologyGenetic Variationvirus diseasesSequence Analysis DNAHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesCD4 Lymphocyte CountChronic infectionInfectious DiseasesImmunologyCoinfectionRNA ViralVirus Research
researchProduct

Risk Factors and Outcome among a Large Patient Cohort with Community-Acquired Acute Hepatitis C in Italy

2006

Background The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated. Methods To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (+/- SD) period of 14+/-15.8 months. Biochemical liver tests were performed, and HCV RNA levels were monitored. Result…

AdultMaleMicrobiology (medical)medicine.medical_specialtyHepatitis C virusHepacivirus.medicine.disease_causeAsymptomaticMED/17 Malattie infettiveRisk FactorsInternal medicineEpidemiologyHumansMedicineRisk factorHepatitisbusiness.industryTransmission (medicine)Hepatitis CMiddle Agedmedicine.diseaseHepatitis CCommunity-Acquired InfectionsChronic infectionInfectious DiseasesItalyAcute DiseaseImmunologyFemalemedicine.symptombusinessClinical Infectious Diseases
researchProduct

TpF1 from Treponema pallidum Activates Inflammasome and Promotes the Development of Regulatory T Cells

2011

Abstract Human syphilis is a multistage disease, with diverse and wide-ranging manifestations caused by Treponema pallidum. Despite the fact that a cell-mediated immune response takes part in the course of syphilis, T. pallidum often manages to evade host immunity and, in untreated individuals, may trigger chronic infection. With this study, we demonstrate for the first time, to our knowledge, that Treponema pallidum induces a regulatory T (Treg) response in patients with secondary syphilis and we found that the miniferritin TpF1, produced by the bacterium, is able to expand this response and promote the production of TGF-β. Accordingly, TpF1 stimulates monocytes to release IL-10 and TGF-β,…

AdultMaleMultiprotein complexInflammasomesVirulence FactorsCellsT-LymphocytesImmunologyAdult; Antigens Helminth; Cell Differentiation; Cells Cultured; Down-Regulation; Female; Humans; Inflammasomes; Inflammation Mediators; Male; Middle Aged; Monocytes; Syphilis; T-Lymphocytes Regulatory; Transforming Growth Factor beta; Treponema pallidum; Virulence FactorsDown-RegulationBiologyT-Lymphocytes RegulatoryMonocytesMicrobiologyProinflammatory cytokineImmune systemAntigenTransforming Growth Factor betaHelminthmedicineHumansImmunology and AllergySyphilisTreponema pallidumAntigensCells CulturedCulturedTreponemaCell DifferentiationInflammasomeMiddle Agedbiology.organism_classificationmedicine.diseaseRegulatoryChronic infectionAntigens HelminthImmunologyFemaleSyphilisInflammation Mediatorsmedicine.drugThe Journal of Immunology
researchProduct

Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection.

2009

Summary.  B-lymphocyte stimulator/B activating factor (BLyS/BAFF) is a tumour necrosis factor-family cytokine that plays a key role in generating and maintaining the mature B-cell pool. BLyS/BAFF expression by macrophages is stimulated by interferon-γ and interleukin-10, and its serum levels are increased in chronic hepatitis C (CHC). The aim of this study was to assess serum levels of BLyS/BAFF in patients with acute hepatitis C (AHC) and correlate them with disease outcome. We studied 28 patients with AHC (14 males, mean age 59.3 ± 15 years), followed for at least 7 months since onset, comparing them with 86 CHC patients and 25 healthy blood donors (HBD). BLyS/BAFF levels were assessed at…

AdultMaleNecrosismedicine.medical_treatmentAcute hepatitis CVirusYoung AdultVirologyB-Cell Activating FactorMedicineHumansIn patientB-cell activating factorAgedAged 80 and overHepatologybusiness.industryHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CChronic infectionInfectious DiseasesCytokineImmunologyFemaleAcute hepatitis Cmedicine.symptombusinessBiomarkersJournal of viral hepatitis
researchProduct

Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study*.

2005

Summary.  We carried out a multicentre study on 2830 patients with chronic liver disease from 79 liver units (25 in northern, 24 in central and 30 in southern Italy) to evaluate naturally acquired immunity against hepatitis A virus (HAV) in relation to age, sex, geographical area of origin and entity of liver disease, and to define the strategy for specific vaccination. Antibody to HAV (anti-HAV) was detected in 1514 (53.5%) of the 2830 patients tested; the prevalence was 50.4% in males and 59.1% in females. Both in central and southern Italy the prevalence of anti-HAV positive subjects increased with increasing age from 43.3 and 44.7%, respectively, in the 0–30-year-old subjects to 80.1 an…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentHepatitis A AntibodiesChronic liver diseaseLiver diseaseSeroepidemiologic StudiesVirologyInternal medicinePrevalencemedicineHumansIn patientChildChronic liver disease HAV infection HAV vaccination HBV chronic infection HCV chronic infection Total anti-HAVAgedAged 80 and overHigh prevalenceHepatologybiologybusiness.industryLiver DiseasesInfantHepatitis AHepatitis AMiddle Agedmedicine.diseaseVaccinationCross-Sectional StudiesInfectious DiseasesItalyChild PreschoolImmunoglobulin GChronic DiseaseImmunologybiology.proteinFemaleAntibodybusinessHepatitis A Virus Human
researchProduct

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

2006

Early treatment of acute hepatitis C with interferon alpha-2b for 24 weeks prevents chronic infection in almost all patients. Because pegylated interferons have replaced conventional interferon in the therapy of chronic hepatitis C, the aim of this study was to analyze the efficacy of an early treatment of acute hepatitis C with peginterferon alpha-2b. Between February 2001 and February 2004, 89 individuals with acute HCV infection were recruited at 53 different centers in Germany. Patients received 1.5 microg/kg peginterferon alpha-2b for 24 weeks; treatment was initiated after a median of 76 days after infection (range 14-150). End-of-treatment response and sustained virological response …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentPegylated interferon alpha-2b610 MedizinInterferon alpha-2GastroenterologyPolyethylene GlycolsInterferonInternal medicineMedicineHumansAgedHepatologybusiness.industryInterferon-alphaMiddle AgedHepatitis CRecombinant ProteinsClinical trialChronic infectionCytokineImmunologyAcute DiseasePopulation studyPatient ComplianceFemaleViral diseaseAcute hepatitis Cbusinessmedicine.drugHepatology (Baltimore, Md.)
researchProduct

HCV genotype 5: an orphan virus

2013

HCV genotype 5 (HCV-5) is the least known HCV genotype. It is found mainly in South Africa and in restricted areas of Belgium, Spain, France, Syria and Greece. Sporadic cases are reported worldwide. The main modes of transmission are blood transfusion and iatrogenic causes. Little is known about its origin, but various studies have elucidated its spread worldwide. In endemic areas, patients infected with HCV-5 are on average older and have a higher viral load and more advanced fibrosis than those infected with non-HCV-5 genotypes. The current standard of care for HCV-5 chronic infection is 48 weeks of dual therapy with pegylated interferon plus ribavirin. ‘Favourable’ Il28B polymorphisms a…

Blood transfusionGenotypemedicine.medical_treatmentHepacivirusAntiviral Agentschemistry.chemical_compoundPegylated interferonGenotypemedicinePrevalenceHumansPharmacology (medical)PharmacologyTransmission (medicine)business.industryRibavirinvirus diseasesHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseasesChronic infectionInfectious DiseasesTreatment OutcomechemistryImmunologyHost-Pathogen InteractionsbusinessViral loadmedicine.drug
researchProduct